Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Analytical Test Series Would Allow Characterization Of Follow-On Biologics – GPhA

This article was originally published in The Pink Sheet Daily

Executive Summary

"No 'one' analytical method is currently capable of such comprehensive analysis," a Generic Pharmaceutical Association white paper states. Previously reported characterization problems were due to inappropriate or misinterpreted tests, GPhA maintains.

You may also be interested in...



BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics

The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.

BIO Opposes Terms "Comparability" & "Therapeutic Equivalence" For Follow-On Biologics

The industry organization continues to emphasize the need for full clinical testing for follow-on biologics. BIO acknowledges that an abbreviated regulatory process may be possible in the future for certain follow-on products.

J&J Hopes Eprex Experience Will Influence Follow-On Biologics Regulatory Pathway

Johnson & Johnson is discussing its Eprex manufacturing complications in Europe with regulators working to develop a follow-on biologics pathway

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel